MA43289B1 - Insuline à action prolongée et utilisation associée - Google Patents

Insuline à action prolongée et utilisation associée

Info

Publication number
MA43289B1
MA43289B1 MA43289A MA43289A MA43289B1 MA 43289 B1 MA43289 B1 MA 43289B1 MA 43289 A MA43289 A MA 43289A MA 43289 A MA43289 A MA 43289A MA 43289 B1 MA43289 B1 MA 43289B1
Authority
MA
Morocco
Prior art keywords
long
insulin
acting insulin
associated use
acting
Prior art date
Application number
MA43289A
Other languages
English (en)
Inventor
Sung Youb Jung
Sang Youn Hwang
Euh Lim Oh
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MA43289B1 publication Critical patent/MA43289B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne : un analogue de l'insuline dans lequel la force de liaison au récepteur de l'insuline est réduite afin d'augmenter la demi-vie de l'insuline dans le sang ; une insuline à action prolongée utilisant celui-ci ; un complexe ; et un procédé de préparation de l'insuline à action prolongée.
MA43289A 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée MA43289B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140006938 2014-01-20
PCT/KR2015/000576 WO2015108398A1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée

Publications (1)

Publication Number Publication Date
MA43289B1 true MA43289B1 (fr) 2019-12-31

Family

ID=53543214

Family Applications (3)

Application Number Title Priority Date Filing Date
MA39301A MA39301A1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée
MA43289A MA43289B1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée
MA46146A MA46146A1 (fr) 2014-01-20 2015-01-20 Insuline a action prolongée et utilisation associée

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA39301A MA39301A1 (fr) 2014-01-20 2015-01-20 Insuline à action prolongée et utilisation associée

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA46146A MA46146A1 (fr) 2014-01-20 2015-01-20 Insuline a action prolongée et utilisation associée

Country Status (22)

Country Link
US (1) US10253082B2 (fr)
EP (1) EP3098235A4 (fr)
JP (1) JP2017505141A (fr)
KR (1) KR102406654B1 (fr)
CN (2) CN105916877A (fr)
AU (1) AU2015206890B2 (fr)
BR (1) BR112016016578A2 (fr)
CA (1) CA2937168A1 (fr)
CL (1) CL2016001844A1 (fr)
CR (1) CR20160376A (fr)
DO (1) DOP2016000176A (fr)
EA (1) EA201691374A1 (fr)
EC (1) ECSP16068524A (fr)
IL (1) IL246782B (fr)
MA (3) MA39301A1 (fr)
MX (1) MX369656B (fr)
MY (1) MY186251A (fr)
PE (1) PE20161153A1 (fr)
PH (1) PH12016501414B1 (fr)
SG (1) SG11201605680PA (fr)
WO (1) WO2015108398A1 (fr)
ZA (1) ZA201605626B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106458996B (zh) 2014-01-20 2020-11-03 克里弗生物科学公司 作为p97复合物的抑制剂的稠合嘧啶
CN108064173B (zh) 2014-11-21 2021-05-18 默沙东公司 胰岛素受体部分激动剂
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
UY36870A (es) * 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
EP3341405A4 (fr) * 2015-09-24 2019-05-01 Hanmi Pharm. Co., Ltd. Procédé de production d'insuline
EP3517544A4 (fr) * 2016-09-23 2020-06-03 Hanmi Pharm. Co., Ltd. Analogue d'insuline ayant une force de liaison réduite au récepteur d'insuline et son utilisation
BR112019016077A2 (pt) * 2017-02-03 2020-03-31 Hanmi Pharm. Co., Ltd. Conjugado da fórmula 1, método para preparar o conjugado, preparação de atuação longa, preparação para prevenir ou tratar diabetes e método para tratar diabetes
EP3604328A4 (fr) * 2017-03-23 2021-01-06 Hanmi Pharm. Co., Ltd. Complexe d'analogue à l'insuline à affinité réduite pour le récepteur de l'insuline et son utilisation
WO2019066603A1 (fr) * 2017-09-29 2019-04-04 한미약품 주식회사 Conjugué de protéine persistant à efficacité améliorée
KR102646845B1 (ko) 2018-08-08 2024-03-14 주식회사 대웅제약 클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법
KR102666154B1 (ko) * 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
BR112021011050A2 (pt) 2018-12-11 2021-08-31 Sanofi Ligante peptídico
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN118271419A (zh) * 2020-03-31 2024-07-02 韩美药品株式会社 新型免疫刺激il-2类似物
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175145A (en) 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE60016560T2 (de) 1999-01-06 2005-12-15 Genentech, Inc., South San Francisco Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
BRPI0409600A (pt) * 2003-04-29 2006-04-18 Lilly Co Eli análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
EP1648933B1 (fr) * 2003-07-25 2009-06-17 ConjuChem Biotechnologies Inc. Derives de l'insuline longue duree et procedes associes
JP4870569B2 (ja) 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
WO2007020256A1 (fr) 2005-08-16 2007-02-22 Novo Nordisk A/S Procede permettant de realiser des polypeptides d'insuline matures
EP2049149B1 (fr) * 2006-07-31 2015-04-15 Novo Nordisk A/S Insulines pegylées à extensions
WO2008049711A1 (fr) * 2006-10-27 2008-05-02 Novo Nordisk A/S Insuline à peptide ajouté
US7790677B2 (en) 2006-12-13 2010-09-07 Elona Biotechnologies Insulin production methods and pro-insulin constructs
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP5688969B2 (ja) * 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
EP2017288A1 (fr) 2007-07-16 2009-01-21 Novo Nordisk A/S Analogues de l'insuline pégylés, stabilisés à la protéase
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2178912B1 (fr) 2007-08-15 2015-07-08 Novo Nordisk A/S Analogues de l'insuline comprenant un fragment acyle et alkylène glycol
PL2209800T3 (pl) 2007-11-16 2013-12-31 Novo Nordisk As Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
EP2229407B1 (fr) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
JP5695909B2 (ja) 2008-01-09 2015-04-08 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009112583A2 (fr) * 2008-03-14 2009-09-17 Novo Nordisk A/S Analogues de l’insuline stabilisés une protéase
WO2009115469A1 (fr) 2008-03-18 2009-09-24 Novo Nordisk A/S Analogues de l'insuline acylés stabilisés vis-à-vis des protéases
US8993516B2 (en) * 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
CA2744558A1 (fr) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Promedicaments insuliniques a base d'amide
EP2411054A2 (fr) 2009-03-27 2012-02-01 Glaxo Group Limited Fusions de médicament et conjugués afférents
US20120184488A1 (en) * 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
KR101058209B1 (ko) 2009-12-30 2011-08-22 전자부품연구원 Ｏｆｄｍ 방식의 디지털 방송 시스템의 빠른 동기 방법
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101330868B1 (ko) 2010-06-08 2013-11-18 한미사이언스 주식회사 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체
KR101324828B1 (ko) 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
AU2011268327B2 (en) * 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
EP2598527A4 (fr) 2010-07-28 2014-01-08 Smartcells Inc Polypeptides d'insuline exprimés de façon recombinante et utilisations de ceux-ci
PE20140969A1 (es) 2011-01-20 2014-07-24 Zealand Pharma As Combinacion de analogos del glucagon acilados con analogos de insulina
BR112013021804A2 (pt) 2011-03-02 2017-03-28 Oerlikon Trading Ag Trübbach "componente corrediço compreendendo revestimento previsto para ficar em contato pelo menos parcialmente com lubrificante, seu sistema tribológico e seu uso"
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
JP2014519002A (ja) 2011-05-03 2014-08-07 テイジン・アラミド・ビー．ブイ． 防弾パネル
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
MX346957B (es) 2011-06-02 2017-04-06 Prolor Biotech Inc Agonistas de receptor de glp-1/glucagón de acción prolongada.
ES2692187T3 (es) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de obesidad que lo comprende
KR101577734B1 (ko) 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
WO2013089463A1 (fr) 2011-12-16 2013-06-20 Lg Innotek Co., Ltd. Procédé de dépôt de carbure de silicium et tranche épitaxiale de carbure de silicium
EP2804621A4 (fr) 2012-01-20 2015-11-18 Univ Case Western Reserve Analogues de l'insuline stabilisés par l'acide glutamique
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
WO2014049610A2 (fr) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides en tant que triples agonistes des récepteurs de gip, glp-1 et glucagon
WO2014073842A1 (fr) 2012-11-06 2014-05-15 Hanmi Pharm. Co., Ltd. Formulation liquide d'un conjugué protéique comprenant l'oxyntomoduline et un fragment d'immunoglobuline
WO2014133324A1 (fr) * 2013-02-26 2014-09-04 한미약품 주식회사 Analogue novateur de l'insuline et son utilisation
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
KR101676542B1 (ko) 2014-12-30 2016-11-16 건국대학교 산학협력단 프로인슐린의 면역학적 용도

Also Published As

Publication number Publication date
SG11201605680PA (en) 2016-09-29
PE20161153A1 (es) 2016-10-27
KR20150087130A (ko) 2015-07-29
CN105916877A (zh) 2016-08-31
AU2015206890A1 (en) 2016-08-04
IL246782B (en) 2020-01-30
US20170101455A1 (en) 2017-04-13
CN116987172A (zh) 2023-11-03
EA201691374A1 (ru) 2016-12-30
AU2015206890B2 (en) 2019-05-23
CA2937168A1 (fr) 2015-07-23
ZA201605626B (en) 2017-11-29
US10253082B2 (en) 2019-04-09
MA39301A1 (fr) 2018-01-31
MY186251A (en) 2021-06-30
CL2016001844A1 (es) 2017-01-06
EP3098235A4 (fr) 2017-10-18
PH12016501414A1 (en) 2016-09-14
KR102406654B1 (ko) 2022-06-10
MX2016009434A (es) 2017-01-18
WO2015108398A1 (fr) 2015-07-23
PH12016501414B1 (en) 2016-09-14
MA46146A1 (fr) 2020-12-31
CR20160376A (es) 2016-10-07
MX369656B (es) 2019-11-15
IL246782A0 (en) 2016-08-31
EP3098235A1 (fr) 2016-11-30
DOP2016000176A (es) 2017-02-15
BR112016016578A2 (pt) 2017-10-03
ECSP16068524A (es) 2018-11-30
JP2017505141A (ja) 2017-02-16

Similar Documents

Publication Publication Date Title
MA43289B1 (fr) Insuline à action prolongée et utilisation associée
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
EA201991696A1 (ru) Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения
MX2016016868A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagon.
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
BR112017025529A2 (pt) agentes de ligação ao tigit e usos destes
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EA201890676A1 (ru) Агонисты глюкагонового рецептора
MX2017007522A (es) Compuestos moduladores del receptor x farnesoide (frx) (receptor nr1h4) novedosos.
BR112016023948A2 (pt) proteínas fc multiméricas
AR102712A1 (es) Agonistas parciales del receptor de insulina
PE20151871A1 (es) Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos
MX2016013323A (es) Uso medico de compuestos de artemisinina y agonistas de gefirina.
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
DK3207052T3 (da) Biosensor baseret på gbetagamma-interagerende proteiner til at monitorere g-proteinaktivering
BR112019010128A2 (pt) proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas
TWD166474S (zh) 手錶
FR3046048B1 (fr) Dispositif et procede pour la mesure de la concentration d'un compose present dans le sang
PE20160787A1 (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
DK3615938T3 (da) Modificerede dextraner til anvendelse i optiske glucoseassays
BR112019006127A2 (pt) anticorpos anti-rankl e usos destes
Chandan Diabetes Mellitus and the implications of modern insulin therapies
TWD175451S (zh) 錶帶之連接件